Industry

JERSEY CITY, N.J.–(BUSINESS WIRE)–Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON® (etonogestrel implant), which is indicated for use by women of reproductive … [Read more…]

2 Night Only Art Exhibition in Hollywood, January 20 and 21, 6:00 p.m. – 9:00 p.m. LOS ANGELES–(BUSINESS WIRE)–“Bloom,” a multi-sensory art experience that converts two physical murals into living, breathing works of art, will land for a two night only exhibition in Hollywood, California, on Tuesday and Wednesday, January 20th and 21st. Created in … [Read more…]

Susan G. Komen® Applauds Bill Introduction, Urges Quick Passage PHOENIX–(BUSINESS WIRE)–Susan G. Komen®, the world’s leading breast cancer organization commends Senator Hildy Angius (R-Bullhead City) for introducing legislation to ensure equitable access to required diagnostic and supplemental breast imaging, by eliminating the financial barriers patients face in accessing needed breast cancer screening. The exorbitant out-of-pocket … [Read more…]

NEW YORK–(BUSINESS WIRE)–Colgate-Palmolive Company (NYSE:CL) will provide a live webcast of its 2025 fourth quarter and full year earnings conference call on Friday, January 30, 2026, at 8:30 a.m. ET. The call will be hosted by Chairman, President and CEO, Noel Wallace, Chief Financial Officer, Stan Sutula, and Chief Investor Relations Officer and EVP, M&A, … [Read more…]

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing complete response of 7 and 15 months after receiving a total of eight doses four cycles of CD19 CAR-NK plus rituximab, with no further treatment thereafter The first chemotherapy free, … [Read more…]

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #earnings–Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously announced, in light of Hologic’s pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Data Integrity Auditor Masterclass Training Course (Apr 22nd – Apr 23rd, 2026)” training has been added to ResearchAndMarkets.com’s offering. Data integrity has received more attention than ever before in the last decade and has become the most critical audit topic for health authorities. Although data integrity has started to gain importance in recent … [Read more…]

DUBLIN, Ohio–(BUSINESS WIRE)–FillPoint Health, a URAC- and ACHC-accredited specialty pharmacy and management services organization (MSO) and a Lyceum Company, has announced the continued expansion of its strategic partnership with US Heart & Vascular (USHV) to advance patient access to innovative therapies across complex and underserved cardiovascular disease categories. This collaboration reflects a shared commitment to … [Read more…]

U.S. FDA grants approval to complete enrollment in EndoQuest’s ongoing PARADIGM Trial following the clinical study’s favorable interim safety review HOUSTON–(BUSINESS WIRE)–EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the next and final stage of its pivotal multicenter … [Read more…]

LEXINGTON, Mass.–(BUSINESS WIRE)–$AGEN #BAL—Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. The collaboration provides Agenus with strategic capital and committed, … [Read more…]